Prolymphocytic leukemia. Response to asparaginase

Area of Science:

• Hematology
• Oncology

Background:

• Chronic lymphocytic leukemia (CLL) patient presented with a high lymphocyte count.
• Diagnosis confirmed as prolymphocytic leukemia of the null cell type based on morphology and surface markers.

Observation:

• The leukemia was refractory to standard treatments including alkylating agents, combination chemotherapy, and leukapheresis.
• Initial therapy with prednisone and vincristine sulfate showed no significant effect.

Findings:

• Addition of asparaginase to prednisone and vincristine sulfate resulted in a rapid and dramatic response.
• Peripheral lymphocyte count decreased from 980 X 10(9)/L to 20 X 10(9)/L within two weeks.
• Restoration of polymorphonuclear leukocyte concentration towards normal levels was observed.

Implications:

• Asparaginase demonstrates significant efficacy in a treatment-resistant case of prolymphocytic leukemia.
• Suggests considering asparaginase as an initial induction therapy for prolymphocytic leukemia of the null cell type.
• Highlights a potential new therapeutic strategy for this rare leukemia subtype.